Tamtam Try Tamtam free
23andMe logo

23andMe account plan

Genetic testing and research

At a glance

23andMe is a consumer DNA testing and genetic research business, run as a nonprofit with more than 11 million research participants.

23andMe sells personalized DNA testing and runs genetic research services for consumers and scientists. Since July 2025 it is owned by TTAM Research Institute, a California nonprofit founded and led by co-founder Anne Wojcicki, which bought the business lines out of the Chapter 11 case of 23andMe Holding Co. for $305 million. The nonprofit now operates as 23andMe Research Institute, a 501(c)(3) research organization based in Palo Alto. It says it has more than 11 million consented research participants; no revenue or profit figures are published in the documents read.

Business units

Strategic priorities

Grow the research cohort
Anne Wojcicki says the company is at 14 million people and points to a hundred million as the next milestone, because AI models for DNA need far larger datasets.
Disease prediction and prevention
Wojcicki says 23andMe is very focused on one area, disease prediction, so people at risk can be found and disease caught at the earliest stages.
Open genetic data to qualified researchers
The Institute says it is working with qualified researchers and is committed to expanding access to genetic and phenotypic data, including links to de-identified real-world health data.
Recruit participants for external studies
The Institute is the recruitment partner for the Wellderly Brain Study, which plans to screen and randomize roughly 1,200 at-risk participants over an estimated 14-16 months.
Stay a neutral, trusted data owner
Wojcicki says the owner of genetic information should not be owned by a single pharma company. TTAM committed to customer choice and transparency, including the option to change a decision on research participation.

Latest results

The documents give no financial results. The latest operating news is from autumn 2026: on 2026-10-13 the Institute formed a Scientific Advisory Board, on 2026-10-19 it announced its ASHG 2026 presentations, citing more than 11 million consented research participants, and on 2026-11-11 it announced the Scripps Alzheimer's prevention partnership.

Investments and deals

Acquisition out of bankruptcy
TTAM Research Institute completed the acquisition of the Personal Genome Service and Research Services business lines on 2025-07-14 for $305 million, after a court approval reported by ABC News on 2025-07-01. It replaced a $256 million bid by Regeneron Pharmaceuticals.
Scientific Advisory Board
Formed in October 2026 with six named members across genomics, AI, gene editing, infectious disease and clinical medicine, alongside the Board of Directors and a Privacy Advisory Board.
Linked health data
Wojcicki says about half a million customers link wearable data, and 50 plus thousand people consent to share medical records, to combine with genetics and AI.

Challenges and risks

Privacy and consent scrutiny
27 states and the District of Columbia sued to block a sale of genetic information without customer consent before the sale was approved. TTAM said it plans to maintain the privacy policies and add further data security measures.
Aftermath of the bankruptcy
23andMe filed for Chapter 11 in March 2025 after a 2023 class-action settlement over a data breach and a mass board resignation in 2024. Wojcicki says she was surprised how many people backed away from helping during the bankruptcy.
Scale of data needed
Wojcicki says 14 million is not enough for the next stage and that models need to be trained on DNA at much larger scale.
Study recruitment is hard
The Scripps release says recruitment can be a significant obstacle in clinical research, which the Institute is positioned to address through its recontactable participant community.

What leadership says

“we're at 14 million today. I point to a hundred million as sort of the next milestone.”

Anne Wojcicki, Founder and CEO of 23andMe Research Institute · Silicon Valley Girl Podcast, 2026-07-28

“This is an extraordinary group of scientific leaders who will help advance our mission to unravel the mysteries of the human genome and make those discoveries accessible to everyone”

Anne Wojcicki, Founder and CEO of 23andMe Research Institute · Scientific Advisory Board press release, 2026-10-13

“With more than 11 million consented participants, we can ask questions that simply weren't answerable before”

Adam Auton, Vice President of Research · ASHG 2026 press release, 2026-10-19

“Our approach allows us to recruit for studies with a level of precision and scale that has traditionally been difficult to achieve”

Noura Abul-Husn, M.D., Ph.D., Chief Medical Officer · Scripps partnership press release, 2026-11-11

Where a supplier can help

Research partnerships and recruitment
Sponsors of clinical studies could use the Institute's recruitment service, tied to its role as recruitment partner for the Wellderly Brain Study and the goal of growing the cohort.
Data and AI infrastructure
Suppliers of secure data platforms and AI tooling for genomic datasets fit the priority of training models on DNA at larger scale and the work on de-identified real-world health data.
Privacy, security and compliance
Security and privacy vendors fit the challenge of consent scrutiny and TTAM's commitment to add data security measures and keep a Privacy Advisory Board.
Health data connections
Connectors for wearable and medical-record data fit the investment in linking customer health data to genetics.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like 23andMe?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about 23andMe

What does 23andMe do?

23andMe offers personalized DNA testing for consumers and research services built on a consented participant community. It operates as the nonprofit 23andMe Research Institute.

Who owns 23andMe?

TTAM Research Institute, a California nonprofit founded and led by Anne Wojcicki, completed the acquisition of the Personal Genome Service and Research Services business lines on 2025-07-14. The price was $305 million.

How many research participants does 23andMe have?

The Institute's October 2026 release cites more than 11 million consented research participants. In July 2026 Wojcicki spoke of 14 million people and a goal of a hundred million.

Who leads 23andMe?

Anne Wojcicki, the co-founder, is Founder and CEO of 23andMe Research Institute. Adam Auton is Vice President of Research and Noura Abul-Husn is Chief Medical Officer.

What is the 23andMe strategy?

The stated focus is disease prediction and prevention, a much larger research cohort, partnerships with researchers, and combining genetics with health data and AI.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-19)